Log in to your Inderes Free account to see all free content on this page.
Lipigon Pharmaceuticals
0.17
SEK
0 %
LPGO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
3 following
0%
+0.59%
-36.37%
-39%
-60.51%
-53.5%
-96.95%
-
-97.7%
www.lipigon.se/investerare
Lipigon Pharmaceuticals operates in the pharmaceutical industry. The company specializes in the research and development of various drug candidates. The product portfolio is broad and includes drugs for rare diseases. These are mainly treatments for diseases caused by disorders in the body's handling of fats. In addition to the main business, service and associated ancillary services are also offered. Lipigon Pharmaceuticals operates worldwide, with the largest presence in the Nordic market.
Revenue
16.41M
EBIT %
-75.38 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LPGO
Daily low / high price
0.17 / 0.17
SEK
Market cap
25.25M SEK
Turnover
808.11 SEK
Volume
4.7K
Financial calendar
Annual report
19.02.2025
Interim report
27.05.2025
Interim report
26.08.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Nordnet Pensionsförsäkring AB | 11.0 % | 11.0 % |
Försäkringsaktiebolaget Avanza Pension | 4.9 % | 4.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Första patienten doserad i Lipigon Pharmaceuticals kliniska fas II-studie med Lipisense®
Lipigon's development partner Leaderna Therapeutics reports last person treated in ongoing Phase 1 study with Lipisense®
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio